ClinicalTrials.gg
CompletedNCT01086384Updated Jan 24, 2018Results posted

Asthma Exacerbation Study

A Phase 3 interventional study of Fluticasone Furoate/GW642444 and Fluticasone furoate in Asthma, sponsored by GlaxoSmithKline. Completed at 183 sites in 11 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2018-01-24.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,020
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 40 studies testing fluticasone furoate in Asthma — none open to participants now, 3 under way, 2 of them phase 3. fluticasone furoate · Asthma.

Enrollment
Largest of 40
2,020 · median 102
Started
2010
with 6 others
Phase 3
14 of 40
none open now
Registered
11th of 40
by date
Lead sponsor
36 of 40
GlaxoSmithKline

Among the 40 studies testing fluticasone furoate in Asthma, this one has the largest enrollment, is one of 7 that started in 2010, is one of 14 in phase 3, and was the 11th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 40 studies testing fluticasone furoate in Asthma is open now. The open studies under Asthma, anywhere →

About fluticasone furoate

fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing fluticasone furoate in Asthma as a file.
02

Study summary

This study will establish the safety as well as demonstrate benefit of the addition of a LABA to an ICS by utilizing an endpoint (time to first severe asthma exacerbation) that informs on both safety and efficacy.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of asthma
  • Reversibility of twelve percent or greater and two hundred milliliters and greater approximately ten to forty minutes following two to four inhalations of albuterol
  • FEV1 of fifty to ninety percent of predicted
  • Currently using inhaled therapy
  • History of one or more asthma exacerbations requiring treatment with oral/systemic corticosteroids or emergency department visit or in-patient hospitalization in previous year

Exclusion criteria

Exclusion Criteria:

  • History of life threatening asthma in previous 5 years (requiring intubation, and/or associated with hypercapnia, hypoxic seizure or respiratory arrest
  • Respiratory infection or oral candidiasis
    • Uncontrolled disease or clinical abnormality
  • Allergies
  • Taking another medication or prohibited medication
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
2,020 participants (actual)

Study arms

  • Experimental
    Fluticasone furoate/GW642444

    Drug: Fluticasone Furoate/GW642444

  • Experimental
    fluticasone furoate

    Drug: Fluticasone furoate

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With 1 or More Severe Asthma Exacerbations

    Asthma is a medical condition that causes narrowing of the small airways in the lungs. A severe asthma exacerbation is defined as a deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days or an in-patient hospitalization or emergency department visit due to asthma that required systemic corticosteroids. Only events deemed by the adjudication committee to be severe asthma exacerbations were used in the analysis of severe asthma exacerbations. The time to the first severe asthma exacerbation was analyzed using a Cox proportional hazards regression model, adjusting for Baseline disease severity (Baseline forced expiratory volume in one second \[FEV1, maximum amount of air forcefully exhaled in one second\]), sex, age, and region.

    Time frame: Baseline to Follow-up (up to 76 weeks of treatment)

Secondary outcomes

  1. Number of Severe Asthma Exacerbations

    A severe asthma exacerbation is defined as a deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days or an in-patient hospitalization or emergency department visit due to asthma that required systemic corticosteroids. A participant may have had one or more exacerbations.

    Time frame: Baseline to Follow-up (up to 76 weeks of treatment)

  2. Change From Baseline in Evening Pre-dose Trough FEV1 at Week 36

    Evening pre-dose trough (lowest value) forced expiratory volume in one second (FEV1) was measured using spirometry equipment that met or exceeded the minimal performance recommendations of the American Thoracic Society. FEV1 is a measure of the maximum amount of air forcefully exhaled in one second. Change from Baseline in evening pre-dose FEV1 was analyzed using an Analysis of Covariance (ANCOVA) model with effects due to Baseline FEV1, sex, age, region, and treatment. Change from Baseline was calculated as the Week 36 value minus the Baseline value.

    Time frame: Baseline and Week 36

07

Results

Posted Sep 11, 2013

Participant flow

2-week Run-in Period
Participant flow — 2-week Run-in Period
MilestoneFP 250 µg/ICSFF 100 µgFF/VI 100/25 µg
Started218300
Completed202000
Not completed16300
Withdrew: Adverse event100
Withdrew: Protocol violation100
Withdrew: Lost to follow-up100
Withdrew: Physician decision600
Withdrew: Withdrawal by subject1900
Withdrew: Study closed/terminated4200
Withdrew: Continuation criteria not met9200
Withdrew: Randomized in error100
Treatment Period
Participant flow — Treatment Period
MilestoneFP 250 µg/ICSFF 100 µgFF/VI 100/25 µg
Started010111009
Completed0863885
Not completed0148124
Withdrew: Withdrawal by subject05355
Withdrew: Protocol violation02617
Withdrew: Lack of efficacy02213
Withdrew: Adverse event01915
Withdrew: Lost to follow-up0119
Withdrew: Physician decision096
Withdrew: Study closed/terminated078
Withdrew: Protocol-defined stopping criteria001
Withdrew: Received treatment in error010

Outcome measures

PrimaryNumber of Participants With 1 or More Severe Asthma Exacerbations

Asthma is a medical condition that causes narrowing of the small airways in the lungs. A severe asthma exacerbation is defined as a deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days or an in-patient hospitalization or emergency department visit due to asthma that required systemic corticosteroids. Only events deemed by the adjudication committee to be severe asthma exacerbations were used in the analysis of severe asthma exacerbations. The time to the first severe asthma exacerbation was analyzed using a Cox proportional hazards regression model, adjusting for Baseline disease severity (Baseline forced expiratory volume in one second \[FEV1, maximum amount of air forcefully exhaled in one second\]), sex, age, and region.

Time frame:
Baseline to Follow-up (up to 76 weeks of treatment)
Reported as:
Number · participants
Number of Participants With 1 or More Severe Asthma Exacerbations
participantsFF 100 µgFF/VI 100/25 µg
Number of Participants With 1 or More Severe Asthma Exacerbations186154
Statistical analysis
  • FF 100 µg vs FF/VI 100/25 µg · Regression cox: 0.795 · 95% CI 0.642 to 0.985The estimated values is the Hazard ratio obtained from the Cox regression analysis for FF/VI 100/25 µg versus FF 100 µg, adjusted for an interim analysis.
  • FF 100 µg vs FF/VI 100/25 µg · Regression, Cox · p = 0.036 (P-value for the Hazard ratio obtained from the Cox regression analysis for FF/VI 100/25 µg versus FF 100 µg, adjusted for an interim analysis.) · Hazard ratio (hr): 15.9 · 95% CI 13.5 to 18.2The estimated value represents the adjusted probability of 1 or more severe asthma exacerbations by Week 52 for FF 100 µg. Cox Proportional Hazards Model estimate at mean Baseline FEV1, age, and proportional coefficients for sex and region.
  • FF 100 µg vs FF/VI 100/25 µg · Regression, Cox · p = 0.036 (P-value for the Hazard ratio obtained from the Cox regression analysis for FF/VI 100/25 µg versus FF 100 µg, adjusted for an interim analysis.) · Cox proportional hazard: 12.8 · 95% CI 10.7 to 14.9The estimated value represents the adjusted probability of 1 or more severe asthma exacerbations by Week 52 for FF/VI 100/25 µg. Cox Proportional Hazards Model estimate at mean Baseline FEV1, age, and proportional coefficients for sex and region.
SecondaryNumber of Severe Asthma Exacerbations

A severe asthma exacerbation is defined as a deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days or an in-patient hospitalization or emergency department visit due to asthma that required systemic corticosteroids. A participant may have had one or more exacerbations.

Time frame:
Baseline to Follow-up (up to 76 weeks of treatment)
Reported as:
Number · Severe asthma exacerbations
Number of Severe Asthma Exacerbations
Severe asthma exacerbationsFF 100 µgFF/VI 100/25 µg
Number of Severe Asthma Exacerbations271200
SecondaryChange From Baseline in Evening Pre-dose Trough FEV1 at Week 36

Evening pre-dose trough (lowest value) forced expiratory volume in one second (FEV1) was measured using spirometry equipment that met or exceeded the minimal performance recommendations of the American Thoracic Society. FEV1 is a measure of the maximum amount of air forcefully exhaled in one second. Change from Baseline in evening pre-dose FEV1 was analyzed using an Analysis of Covariance (ANCOVA) model with effects due to Baseline FEV1, sex, age, region, and treatment. Change from Baseline was calculated as the Week 36 value minus the Baseline value.

Time frame:
Baseline and Week 36
Reported as:
Least squares mean · Liters
Change From Baseline in Evening Pre-dose Trough FEV1 at Week 36
LitersFF 100 µgFF/VI 100/25 µg
Change From Baseline in Evening Pre-dose Trough FEV1 at Week 360.265 ± 0.0140.348 ± 0.014

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FF 100 µg—29/1,010 (2.9%)479/1,010 (47.4%)
FF/VI 100/25 µg—41/1,009 (4.1%)467/1,009 (46.3%)
Most frequent serious events
Showing 10 of 56
Most frequent serious events
EventFF 100 µgFF/VI 100/25 µg
AsthmaRespiratory, thoracic and mediastinal disorders9/101011/1009
PneumoniaInfections and infestations4/10104/1009
Nasal polypsRespiratory, thoracic and mediastinal disorders0/10101/1009
Anal abscessInfections and infestations0/10101/1009
AppendicitisInfections and infestations0/10101/1009
Chronic sinusitisInfections and infestations0/10101/1009
LabyrinthitisInfections and infestations0/10101/1009
Meningitis viralInfections and infestations0/10101/1009
PharyngitisInfections and infestations0/10101/1009
Skin infectionInfections and infestations0/10101/1009
Most frequent other events
Showing 10 of 13
Most frequent other events
EventFF 100 µgFF/VI 100/25 µg
HeadacheNervous system disorders179/1010188/1009
NasopharyngitisInfections and infestations131/1010155/1009
Upper respiratory tract infectionInfections and infestations93/101073/1009
BronchitisInfections and infestations74/101059/1009
CoughRespiratory, thoracic and mediastinal disorders64/101055/1009
Oropharyngeal painRespiratory, thoracic and mediastinal disorders55/101041/1009
InfluenzaInfections and infestations38/101050/1009
SinusitusInfections and infestations38/101042/1009
Back painMusculoskeletal and connective tissue disorders40/101041/1009
PharyngitisInfections and infestations41/101029/1009

Baseline characteristics

Age, Continuous
Age, Continuous(Years)FF 100 µgFF/VI 100/25 µgTotal
Mean42.3 ± 16.8241.1 ± 17.1041.7 ± 16.96
Sex: Female, Male
Sex: Female, Male(Participants)FF 100 µgFF/VI 100/25 µgTotal
Female6896611350
Male321348669
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)FF 100 µgFF/VI 100/25 µgTotal
African American/African Heritage474087
American Indian or Alaska Native4913
Asian - Central/South Asian Heritage022
Asian - East Asian Heritage101
Asian - Japanese Heritage303262
Asian - South East Asian Heritage7978157
Native Hawaiian or other Pacific Islander202
White - Arabic/North African Heritage527
White - White/Caucasian/European Heritage7387381476
Mixed Race104108212
08

Study locations

183 sites
  • GSK Investigational Site
    Birmingham, Alabama 35209, United States
  • GSK Investigational Site
    Mobile, Alabama 36608, United States
  • GSK Investigational Site
    Oxford, Alabama 36203, United States
  • GSK Investigational Site
    Phoenix, Arizona 85016, United States
  • GSK Investigational Site
    Scottsdale, Arizona 85251, United States
  • GSK Investigational Site
    Tucson, Arizona 85724-5073, United States
  • GSK Investigational Site
    Bell Gardens, California 90201, United States
  • GSK Investigational Site
    Fresno, California 93721, United States
  • GSK Investigational Site
    Huntington Beach, California 92647, United States
  • GSK Investigational Site
    Long Beach, California 90808, United States
  • GSK Investigational Site
    Los Angeles, California 90048, United States
  • GSK Investigational Site
    Mission Viejo, California 92691, United States
  • GSK Investigational Site
    Napa, California 94558, United States
  • GSK Investigational Site
    Rancho Mirage, California 92270, United States
  • GSK Investigational Site
    Riverside, California 92506, United States
  • GSK Investigational Site
    Rolling Hills Estates, California 90274, United States
  • GSK Investigational Site
    Roseville, California 95661, United States
  • GSK Investigational Site
    San Diego, California 92120, United States
  • GSK Investigational Site
    Stockton, California 95207, United States
  • GSK Investigational Site
    Torrance, California 90505, United States
  • GSK Investigational Site
    Denver, Colorado 80230, United States
  • GSK Investigational Site
    Englewood, Colorado 80112, United States
  • GSK Investigational Site
    Cocoa, Florida 32927, United States
  • GSK Investigational Site
    Miami, Florida 33173, United States
  • GSK Investigational Site
    Valrico, Florida 33596, United States
  • GSK Investigational Site
    Winter Park, Florida 32789, United States
  • GSK Investigational Site
    Albany, Georgia 31707, United States
  • GSK Investigational Site
    Columbus, Georgia 31904, United States
  • GSK Investigational Site
    Lawrenceville, Georgia 30046, United States
  • GSK Investigational Site
    Coeur d'Alene, Idaho 83814, United States
  • GSK Investigational Site
    River Forest, Illinois 60305, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46256, United States
  • GSK Investigational Site
    Hazard, Kentucky 41701, United States
  • GSK Investigational Site
    Owensboro, Kentucky 42301, United States
  • GSK Investigational Site
    Metairie, Louisiana 70006, United States
  • GSK Investigational Site
    Sunset, Louisiana 70584, United States
  • GSK Investigational Site
    Baltimore, Maryland 21236, United States
  • GSK Investigational Site
    Bronx, New York 10461, United States
  • GSK Investigational Site
    Rockville Center, New York 11570, United States
  • GSK Investigational Site
    Canton, Ohio 44718, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45231, United States
  • GSK Investigational Site
    Sylvania, Ohio 43560, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73103, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73120, United States
  • GSK Investigational Site
    Eugene, Oregon 97401, United States
  • GSK Investigational Site
    Medford, Oregon 97504, United States
  • GSK Investigational Site
    Collegeville, Pennsylvania 19426, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19107, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19115, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15241, United States
  • GSK Investigational Site
    Charleston, South Carolina 29407, United States
  • GSK Investigational Site
    Gaffney, South Carolina 29340, United States
  • GSK Investigational Site
    Spartanburg, South Carolina 29303, United States
  • GSK Investigational Site
    Union, South Carolina 29379, United States
  • GSK Investigational Site
    Knoxville, Tennessee 37909, United States
  • GSK Investigational Site
    Austin, Texas 78750, United States
  • GSK Investigational Site
    Houston, Texas 77054, United States
  • GSK Investigational Site
    Houston, Texas 77074, United States
  • GSK Investigational Site
    Killeen, Texas 76542, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Waco, Texas 76712, United States
  • GSK Investigational Site
    South Burlington, Vermont 05403, United States
  • GSK Investigational Site
    Bellingham, Washington 98225, United States
  • GSK Investigational Site
    La Crosse, Wisconsin 54601, United States
  • GSK Investigational Site
    Quilmes, Buenos Aires B1878FNR, Argentina
  • GSK Investigational Site
    Parana, Entre Ríos E3100BHK, Argentina
  • GSK Investigational Site
    Rosario, Santa Fe S2000DSR, Argentina
  • GSK Investigational Site
    Buenos Aires, C1424BSF, Argentina
  • GSK Investigational Site
    Buenos Aires, C1425BEN, Argentina
  • GSK Investigational Site
    Ciudad Autónoma de Buenos Aires, C1121ABE, Argentina
  • GSK Investigational Site
    Ciudad Autónoma de Buenos Aires, C1426ABP, Argentina
  • GSK Investigational Site
    Mendoza, M5500CCG, Argentina
  • GSK Investigational Site
    Tucuman, 4000, Argentina
  • GSK Investigational Site
    Garran, Australian Capital Territory 2606, Australia
  • GSK Investigational Site
    Blacktown, New South Wales 2148, Australia
  • GSK Investigational Site
    Hornsby, New South Wales 2077, Australia
  • GSK Investigational Site
    Auchenflower, Queensland 4066, Australia
  • GSK Investigational Site
    Toorak Gardens, South Australia 5065, Australia
  • GSK Investigational Site
    Clayton, Victoria 3168, Australia
  • GSK Investigational Site
    Deggingen, Baden-Wuerttemberg 73326, Germany
  • GSK Investigational Site
    Weinheim, Baden-Wuerttemberg 69469, Germany
  • GSK Investigational Site
    Aschaffenburg, Bayern 63739, Germany
  • GSK Investigational Site
    Grossheirath, Bayern 96269, Germany
  • GSK Investigational Site
    Vilshofen, Bayern 94474, Germany
  • GSK Investigational Site
    Cottbus, Brandenburg 03050, Germany
  • GSK Investigational Site
    Potsdam, Brandenburg 14469, Germany
  • GSK Investigational Site
    Ruedersdorf, Brandenburg 15562, Germany
  • GSK Investigational Site
    Frankfurt, Hessen 60389, Germany
  • GSK Investigational Site
    Frankfurt, Hessen 60596, Germany
  • GSK Investigational Site
    Marburg, Hessen 35037, Germany
  • GSK Investigational Site
    Bochum, Nordrhein-Westfalen 44787, Germany
  • GSK Investigational Site
    Dortmund, Nordrhein-Westfalen 44263, Germany
  • GSK Investigational Site
    Essen, Nordrhein-Westfalen 45359, Germany
  • GSK Investigational Site
    Gelsenkirchen, Nordrhein-Westfalen 45879, Germany
  • GSK Investigational Site
    Goch, Nordrhein-Westfalen 47574, Germany
  • GSK Investigational Site
    Solingen, Nordrhein-Westfalen 42651, Germany
  • GSK Investigational Site
    Witten, Nordrhein-Westfalen 58452, Germany
  • GSK Investigational Site
    Koblenz, Rheinland-Pfalz 56068, Germany
  • GSK Investigational Site
    Mainz, Rheinland-Pfalz 55131, Germany
  • GSK Investigational Site
    Rhaunen, Rheinland-Pfalz 55624, Germany

Showing the first 100 of 183 sites across 11 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • O'Byrne PM, Jacques L, Goldfrad C, Kwon N, Perrio M, Yates LJ, Busse WW. Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma. Respir Res. 2016 Nov 24;17(1):157. doi: 10.1186/s12931-016-0473-x. PubMed 27881132 ↗
  • Gross AS, Goldfrad C, Hozawa S, James MH, Clifton CS, Sugiyama Y, Jacques L. Ethnic sensitivity assessment of fluticasone furoate/vilanterol in East Asian asthma patients from randomized double-blind multicentre Phase IIb/III trials. BMC Pulm Med. 2015 Dec 24;15:165. doi: 10.1186/s12890-015-0159-z. PubMed 26704701 ↗
  • Bateman ED, O'Byrne PM, Busse WW, Lotvall J, Bleecker ER, Andersen L, Jacques L, Frith L, Lim J, Woodcock A. Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. Thorax. 2014 Apr;69(4):312-9. doi: 10.1136/thoraxjnl-2013-203600. Epub 2013 Nov 19. PubMed 24253831 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2010, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2013, 2 years after primary completion. A results delay was requested in Jul 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2010
First posted
Mar 15, 2010
Start
Feb 22, 2010
Primary completionActual
Sep 1, 2011
CompletionActual
Sep 15, 2011
Results delay requested
Jul 26, 2012
Results first posted
Sep 11, 2013
Last update
Jan 24, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01086384
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 15, 2010
Start date
Feb 22, 2010
Primary completion
Sep 1, 2011
Completion
Sep 15, 2011
Results posted
Sep 11, 2013
Last update
Jan 24, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluticasone furoate · Vilanterol

Start the discussion